Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
6–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants must have a history of migraine with or without aura as defined by International Headache Society International Classification of Headache Disorders, 3rd edition (ICHD-3) (ICHD-3 2018) diagnostic criteria 1.1 or 1.2.1 and meets the following criteria:
* History of migraine attacks for more than 6 months
* Reports at least 2 and no more than 8 moderate-to-severe migraine attacks per month in the 2 months prior to screening visit
* Duration of a typical untreated migraine attack (excluding sleep) is greater than or equal to 3 hours
* Participant has not, by history, experienced satisfactory response with a previous migraine therapy, in the opinion of the investigator
Participant must be able to swallow a tablet
For participants taking migraine preventive medication, treatment regimen is stable and has been taken for at least 3 months prior to screening
Participants must weigh at least 15 kilograms (kg)
You may not be if
Participants must not be pregnant or nursing
Participants must not have any acute, serious, or unstable medical condition
Participants must not be actively suicidal or at significant risk for suicide, in the opinion of the investigator
Clareo Health | A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
